Association between FSAP 1601G > A polymorphism and venous thromboembolism risk: A meta-analysis

Abstract

Objective

Previous several studies have shown that factor VII-activating protease (FSAP) gene 1601G>A polymorphism is related to the occurrence of venous thromboembolism, but the results are inconsistent and controversial. Therefore, we conducted a meta-analysis to explore the association between FSAP 1601G>A polymorphism and venous thromboembolism susceptibility.

Methods

We managed a systematic literature search through Pubmed, Embase, Web of Science, China National Knowledge Infrastructure, and WanFang databases to collect research data related to FSAP gene 1601G>A polymorphism and susceptibility to venous thromboembolism published before May 2019. Data analysis was performed through Revman 5.3 and Stata 12.0 software, the pooled odd ratios and 95% confidence intervals were calculated. Additionally, the sensitivity analysis and publication bias assessment were also performed.

Results

A total of seven case–control studies were included and evaluated, including 2411 venous thromboembolism cases and 2850 controls. The meta-analysis results revealed that the FSAP 1601G>A mutation is associated with venous thromboembolism risk, and statistically significance was observed under three genetic comparison models (A: G, odds ratio: 1.33, 95% confidence interval: 1.07–1.66; GA: GG, odds ratio: 1.34, 95% confidence interval: 1.06–1.68; and GA + AA: GG, odds ratio: 1.33, 95% confidence interval: 1.06–1.66).

Conclusion

This study demonstrated that the FSAP 1601G>A polymorphism may be associated with venous thromboembolism susceptibility.

Keywords

Factor VII-activating protease polymorphism meta-analysis venous thromboembolism

Get full access to this article

View all access options for this article.

References

Heit

Spencer

White

RH.

The epidemiology of venous thromboembolism.

J Thromb Thrombolysis 2016; 41: 3–14.

Cushman

Tsai

White

, et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med 2004; 117: 19–25.

Silverstein

Heit

Mohr

, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998; 158: 585–593.

Huang

Liu

Jing

, et al. Common genetic risk factors of venous thromboembolism in Western and Asian populations. Genet Mol Res 2016; 15: 15017644.

Choi-Miura

Tobe

Sumiya

, et al. Purification and characterization of a novel hyaluronan-binding protein (PHBP) from human plasma: it has three EGF, a kringle and a serine protease domain, similar to hepatocyte growth factor activator. J Biochem 1996; 119: 1157–1165.

Choi-Miura

Yoda

Saito

, et al. Identification of the substrates for plasma hyaluronan binding protein. Biol Pharm Bull 2001; 24: 140–143.

Sumiya

Asakawa

Tobe

, et al. Isolation and characterization of the plasma hyaluronan-binding protein (PHBP) gene (HABP2). J Biochem 1997; 122: 983–990.

Roemisch

Feussner

Nerlich

, et al. The frequent Marburg I polymorphism impairs the pro-urokinase activating potency of the factor VII activating protease (FSAP). Blood Coagul Fibrinolysis 2002; 13: 433–441.

Trompet

Pons

Kanse

, et al. Factor VII activating protease polymorphism (G534E) is associated with increased risk for stroke and mortality. Stroke Res Treat 2011: 424759. DOI: 10.4061/2011/424759.

10.

Ireland

Miller

Webb

, et al. The factor VII activating protease G511E (Marburg) variant and cardiovascular risk. Thromb Haemost 2004; 92: 986–992.

11.

Kanse

Parahuleva

Muhl

, et al. Factor VII-activating protease (FSAP): vascular functions and role in atherosclerosis. Thromb Haemost 2008; 99: 286–289.

12.

Parahuleva

Kanse

Parviz

, et al. Factor Seven Activating Protease (FSAP) expression in human monocytes and accumulation in unstable coronary atherosclerotic plaques. Atherosclerosis 2008; 196: 164–171.

13.

Willeit

Kiechl

Weimer

, et al. Marburg I polymorphism of factor VII–activating protease: a prominent risk predictor of carotid stenosis. Circulation 2003; 107: 667–670.

14.

Parahuleva

Holschermann

Zandt

, et al. Circulating factor VII activating protease (FSAP) is associated with clinical outcome in acute coronary syndrome. Circ J 2012; 76: 2653–2661.

15.

Ahmad-Nejad

Dempfle

Weiss

, et al. The G534E-polymorphism of the gene encoding the factor VII-activating protease is a risk factor for venous thrombosis and recurrent events. Thromb Res 2012; 130: 441–444.

16.

Hoppe

Tolou

Radtke

, et al. Marburg I polymorphism of factor VII-activating protease is associated with idiopathic venous thromboembolism. Blood 2005; 105: 1549–1551.

17.

van Minkelen

de Visser

Vos

, et al. The Marburg I polymorphism of factor VII-activating protease is not associated with venous thrombosis. Blood 2005; 105: 4898; author reply 9.

18.

Weisbach

Ruppel

Eckstein

The Marburg I polymorphism of factor VII-activating protease and the risk of venous thromboembolism.

Thromb Haemost 2007; 97: 870–872.

19.

Franchi

Martinelli

Biguzzi

, et al. Marburg I polymorphism of factor VII-activating protease and risk of venous thromboembolism. Blood 2006; 107: 1731.

20.

Pecheniuk

Elias

, et al. Failure to validate association of gene polymorphisms in EPCR, PAR-1, FSAP and protein S Tokushima with venous thromboembolism among Californians of European ancestry. Thromb Haemost 2008; 99: 453–455.

21.

Sidelmann

Vitzthum

Funding

, et al. Factor VII-activating protease in patients with acute deep venous thrombosis. Thromb Res 2008; 122: 848–853.